ArticleThe Indian journal of medical research2025
Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.
Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhancing the diagnostic scope of the PathoDetectTM MTB RIF & INH assay: A call for inclusive evaluation.The Indian journal of medical research · 2025Article
- Authors' response.The Indian journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives Tuberculosis (TB) remains a major global health concern, with India accounting for 26 per cent of the global burden. Despite advances, access to rapid molecular diagnostics is limited, and the assays currently used in National TB Elimination Programme (NTEP) do not detect isoniazid (INH) resistance upfront. PathoDetect™ MTB RIF & INH is an indigenous closed-system assay that simultaneously detects Mycobacterium tuberculosis (MTB) and resistance to rifampicin (RIF) and INH. This study evaluated its diagnostic characteristics. Methods In this cross-sectional multicenter study conducted at six TB reference laboratories in India, 1039 participants were enrolled (718 presumptive pulmonary TB, 321 presumptive multidrug resistant TB; MDR-TB). PathoDetect™'s discriminatory ability was assessed using the measures sensitivity and specificity, and its diagnostic performance using positive predictive value (PPV) and negative predictive value (NPV). Liquid culture served as the reference standard for MTB detection, while phenotypic drug susceptibility testing (pDST) and line probe assay (LPA) as reference standards for RIF and INH resistance detection. Results For MTB detection in presumptive pulmonary TB (PTB), PathoDetect™ showed a sensitivity of 98.1 per cent [95% confidence interval (CI): 96.1-99.2], specificity of 94.2 per cent (95% CI: 91-96.5), PPV of 94.9 per cent (95% CI: 92.2-96.9), and NPV of 97.8 per cent (95% CI: 95.5-99.1) with near-perfect agreement with Truenat® (k=0.89). Among 514 confirmed TB cases, PathoDetect™ detected RIF resistance with a sensitivity of 86.5 per cent (95% CI: 80.2-91.5), specificity of 91.6 per cent (95% CI: 88.2-94.3), PPV of 82.3 per cent (95% CI: 75.6-87.8), and NPV of 93.8 per cent (95% CI: 90.7-96.1). For INH resistance, sensitivity was 88.9 per cent (95% CI: 84.1-92.6), specificity 87 per cent (95% CI: 82.4-90.8), PPV 85.6 per cent (95% CI: 80.5-89.8), and NPV 90 per cent (95% CI: 85.7-93.4) using pDST as reference. Truenat® MTB-RIF showed comparable performance for RIF resistance detection (k=0.75). Compared to line probe assay (LPA), PathoDetect™ demonstrated higher sensitivity (93.4 vs. 88.8%), specificity (98.2 vs. 93.9%), PPV (96.1 vs. 86.8%) and NPV (97 vs. 94.9%) for RIF resistance detection over Truenat®. Interpretation & conclusions PathoDetect™ is a reliable molecular diagnostic tool for detection of MTB and resistance to RIF & INH. The assay showed better RIF resistance detection compared to INH. Its high sensitivity and specificity indicate strong discriminatory ability, while PPV and NPV demonstrate reasonably good diagnostic performance in the study population. These findings support PathoDetect™ as a promising alternative for rapid TB diagnosis, particularly in high-burden settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.